Intellia Therapeutics (NTLA)

• Market cap: $968M
• 1 day: 0.85%
• 5 days: -6.03%
• 1 month: -27.65%
• 3 months: -54.72%
• 6 months: -65.28%
• Year to date: -22.26%
• 1 year: -63.09%
• 5 years: -35.06%
• 10 years: -57.01%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Employees: 598

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

28% more repeat investments, than reductions

Existing positions increased: 109 | Existing positions reduced: 85

3% less funds holding

Funds holding: 287 [Q2] → 278 (-9) [Q3]

4.15% less ownership

Funds ownership: 96.5% [Q2] → 92.35% (-4.15%) [Q3]

8% less capital invested

Capital invested by funds: $2.08B [Q2] → $1.93B (-$157M) [Q3]

11% less first-time investments, than exits

New positions opened: 42 | Existing positions closed: 47

25% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 3 (-1) [Q3]

48% less call options, than puts

Call options by funds: $11M | Put options by funds: $20.9M

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 26% upside
• Avg. target: $45 373% upside
• High target: $91 858% upside

10 analyst ratings

• positive: 6 60%
• neutral: 4 40%
• negative: 0 0%

Goldman Sachs Salveen Richter 13% 1-year accuracy 2 / 16 met price target	26% upside $12	Neutral Maintained	14 Jan 2025
Oppenheimer Jay Olson 20% 1-year accuracy 21 / 104 met price target	321% upside $40	Outperform Maintained	13 Jan 2025
BMO Capital Kostas Biliouris 22% 1-year accuracy 5 / 23 met price target	426% upside $50	Outperform Maintained	10 Jan 2025
Wells Fargo Yanan Zhu 0% 1-year accuracy 0 / 16 met price target	532% upside $60	Overweight Maintained	10 Jan 2025
Canaccord Genuity Whitney Ijem 18% 1-year accuracy 7 / 40 met price target	847% upside $90	Buy Maintained	19 Nov 2024